 |
|||||
|
|||||
|
|||||
|
|||||
|
|||||
The Journal of Neuroscience, June 15, 2003, 23(12):5020-5030
Previous Article | Next Article
Calpain Is a Major Cell Death Effector in Selective Striatal Degeneration Induced In Vivo by 3-Nitropropionate: Implications for Huntington's Disease
Nicolas Bizat,1 Jean-Michel Hermel,1 Frédéric Boyer,1 Carine Jacquard,1 Christophe Créminon,2 Stéphane Ouary,1 Carole Escartin,1 Philippe Hantraye,1,3 Stan Krajewski,4 andEmmanuel Brouillet1 1Unité de Recherche Associée Commissariat à l'Energie Atomique (CEA)-Centre National de la Recherche Scientifique 2210, Service Hospitalier Frédéric Joliot, Département de Recherche Médicale (DRM), Direction des Sciences du Vivant (DSV), CEA, 91401 Orsay, France, 2CEA, Service de Pharmacologie et d'Immunologie, DRM, DSV, Centre d'Etudes Nucléaires Saclay, 91191 Gif sur Yvette, France, 3CEA, Isotopic Imaging, Biochemical and Pharmacology Unit, Service Hospitalier Frédéric Joliot, DRM, DSV, CEA, 91401 Orsay, France, and 4Program on Cell Death and Apoptosis, The Burnham Institute, La Jolla, California 92037
Abstract
Top
Abstract
Introduction
Striatal cell death in Huntington's Disease (HD) may involve mitochondrial defects, NMDA-mediated excitotoxicity, and activation of death effector proteases such as caspases and calpain. However, the precise contribution of mitochondrial defects in the activation of these proteases in HD is unknown. Here, we addressed this question by studying the mechanism of striatal cell death in rat models of HD using the mitochondrial complex II inhibitor 3-nitropropionic acid (3-NP). The neurotoxin was either given by intraperitoneal injections (acute model) or over 5 d by constant systemic infusion using osmotic pumps (chronic model) to produce either transient or sustained mitochondrial deficits. Caspase-9 activation preceded neurodegeneration in both cases. However, caspase-8 and caspase-3 were activated in the acute model, but not in the chronic model, showing that 3-NP does not require activation of these caspases to produce striatal degeneration. In contrast, activation of calpain was specifically detected in the striatum in both models and this was associated with a calpain-dependent cleavage of huntingtin. Finally, in the chronic model, which mimics a steady blockade of complex II activity reminiscent of HD, selective calpain inhibition prevented the abnormal calpain-dependent processing of huntingtin, reduced the size of the striatal lesions, and almost completely abolished the 3-NP-induced DNA fragmentation in striatal cells. The present results demonstrate that calpain is a predominant effector of striatal cell death associated with mitochondrial defects in vivo. This suggests that calpain may play an important role in HD pathogenesis and could be a potential therapeutic target to slow disease progression.
Key words: neurodegenerative disease; excitotoxicity; mitochondrial complex II inhibitor; calpain; caspase; calpain inhibitor; neuroprotection
Introduction
Huntington's disease (HD) is a genetic disorder associated with severe motor and cognitive deficits and preferential degeneration of medium spiny GABAergic neurons located in the striatum (Harper, 1991). Whereas the genetic defect responsible for HD is identified as an expansion of polyglutamine sequences within the huntingtin (Htt) protein (Huntington's Disease Collaborative Research Group, 1993
Mechanisms of cell death specifically implicated in HD pathogenesis include oxidative stress, mitochondrial defects, excitotoxicity, and activation of death effector proteases. The mitochondrial defects most consistently found in HD involve the succinate dehydrogenase-complex II and Ca2+ homeostasis (Gu et al., 1996
To address this question, we used 3-NP-mediated succinate dehydrogenase (SDH) inhibition in rats as a mean to produce either transient (acute model) or sustained (chronic model) mitochondrial deficits and characterized the pattern of caspase and calpain activation, in relation to these different patterns of mitochondrial perturbation. We found evidence for a regionally restricted calpain activation in both models in vivo. We then examined whether inhibiting calpain in vivo could also specifically protect the striatum in the chronic model of mitochondrial blockade.
Materials and Methods
Animals. We used 12-week-old male Lewis rats (Iffa Credo, L'Arbresle, France) weighing 340–370 gm. All experimental procedures were performed in strict accordance with the recommendations of the European Community (86/609/EEC) and the French National Committee (87/848) for care and use of laboratory animals.All chemicals and reagents were purchased from Sigma (L'Isle d'Abeau Chesnes, France) unless specified otherwise.
3-NP treatment and experimental design. Two different 3-NP-rat models were studied.
In the chronic model, a solution of 3-NP was delivered by chronic infusion (54 mg · kg -1 · d -1) using osmotic minipumps (flow rate 10 µl/hr, model 2ML1; Alzet, Palo Alto, CA) placed subcutaneously in the back of the animals under ketamine–xylazine anesthesia (Dautry et al., 2000
In the acute model, animals received two intraperitoneal injections of 3-NP (25 mg/ml, pH 7.4, 50 mg/kg) at 90 min intervals. Control animals received intraperitoneal injections of saline. Animals were killed at 3, 6, 12, 24, and 48 hr after the first intraperitoneal injection of the neurotoxin. Rats showed variable responses to this acute 3-NP regimen. In the experiments presented, survival rate over the 48 hr after injection was 87% (time point, n survivor/n per group: 6 hr, 7/7; 12 hr, 7/7; 24 hr, 8/10; 48 hr, 11/14). All rats of the 6 hr group were used for analysis. For later time points, only rats with obvious uncoordination and/or dystonia among survivors were taken for analysis (time point, n symptomatic/n survivors: 12 hr, 7/7; 24 hr, 5/8; 48 hr, 10/11).
Calpain inhibitor I neuroprotection experiments in the chronic model. The calpain inhibitor I (CI-1; z-Leu-Leu-Norleucinal; Biomol, Plymouth Meeting, PA) solubilized in phosphate buffer saline containing 40% dimethylsulfoxide was delivered (2.5 µg/hr, 1 µl/hr) by intracerebroventricular infusion using an osmotic minipump (model 2001; Alzet) connected to a stereotaxically implanted cannula [anteroposterior (AP)–1.6 mm, lateral 2.0 mm from bregma, ventral 3.5 mm from dura, using the "brain infusion kit"; Alzet]. The minipump delivering 3-NP and that delivering CI-1 were implanted simultaneously. Histological and biochemical evaluation was performed on day 5 of the neurotoxic treatment.
Brain processing, sample dissection, and homogenization. Brains were rapidly removed from the skull and cut vertically along the rostrocaudal axis into two hemispheres. The left hemisphere was fixed in Bouin's solution for 3 d and paraffin-embedded for immunohistochemical evaluation. For CI-1 studies, the left hemisphere was frozen in isopentane (-30°C) and stored at–80°C for histological evaluation. Striatum and cortex samples were dissected and processed for biochemical analyses from the right hemisphere. Tissue dissection was carried out on an ice-cooled platform. The lateral striatum and the surrounding cerebral cortex were dissected out from coronal slices (2-mm-thick) (Dautry et al., 2000
Western blot analysis. Protein concentrations were determined using the BCA method (Pierce, Rockford, IL) according to the manufacturer's instructions. Proteins in striatal and cortical fractions were separated by SDS-PAGE as previously described (Hermel et al., 1999
-spectrin; Chemicon, Temecula, CA), huntingtin [1:1000; 4C8 clone, antibody (Ab) 2166; Euromedex, Souffelweyersheim, France], caspase-9 (1:1000; Bur 81 and Bur 73, Krajewski et al., 1999
Immunohistochemistry and histological studies. Caspase-9, -8, and -3 immunohistochemistry and Masson-trichrome staining was performed on paraffin sections as previously described (Krajewski et al., 1999
350 fields of view per section) using an automated motorized stage and acquisition system (Fluovision; IMSTAR, Paris, France). SDH and cytochrome oxidase (COX) histochemistry was performed and quantitatively analyzed as previously described (Greene and Greenamyre, 1995
Oligonucleosome detection. Oligonucleosome contents in soluble fractions (20 µl) were determined using the "ELISA cell death detection kit" (Roche) according to the manufacturer instructions. The results were normalized by the protein concentrations in each sample and expressed as mean OD values ± SEM.
Proteolytic activity assay using fluorogenic substrate for caspases and calpain. The fluorescent assay of the protease activity is based on the cleavage of 7-amino-4-methyl-coumarin (AMC) or 7-amino-4-trifluoro-methyl-coumarin (AFC) dyes from the C terminus of the peptide substrates. The calpain activity was determined using N-succinyl-Leu-Tyr-(N-succinyl-LY)-AMC, a substrate preferentially cleaved by µ/m-calpain (McDonald et al., 2001
10 µl containing
-mercaptoethanol, and 5 mM CaCl2 and is attributable to the cleavage of 150 µM N-succinyl-LY-AMC. The non-calcium-dependent fluorescence was measured under the same conditions using buffer A without calcium and containing 1 mM EDTA and 10 mM EGTA. To measure the inhibiting effects on calpain activity of striatal samples from animals treated in vivo with CI-1 or its vehicle, 10 µl of supernatant was incubated in 90 µl of calpain assay buffer containing purified µ-calpain (0.2 U; Calbiochem). Caspase-3, -8, and -9 activities were tested on peptidic substrates (Biomol), using respectively N-acetyl-Asp-Glu-Val-Asp-AFC (DEVDAFC), N-acetyl-Ile-Glu-Thr-Asp-AFC (IETD-AFC), and N-acetyl-Leu-Glu-His-Asp-AFC (LEHD-AFC). Soluble fractions (30 µg of protein) were incubated at 37°C for 45 min in a caspase buffer B (in mM: 20 HEPES, pH 7.4, 50 NaCl, 0.2 EDTA, and 4 DTT) with 40 µM of the appropriate substrate. The nonspecific activity was considered as the activity remaining in the presence of the fluorogenic substrate and 10 µM of the appropriate caspase inhibitor i.e., the C-terminal aldehyde form (CHO) of the substrate (DEVD-CHO, IETD-CHO, and LEHD-CHO for caspase-3, -8, and–9, respectively). Fluorescence (excitation/emission: 400/505 nm for AFC and 380/460 nm for AMC) was measured in 96 well plates using a "Fusion" fluorimeter (Packard Bioscience, Rungis, France). Enzyme activity was calculated using standard curves of AFC or AMC and expressed as mean activity (picomoles of AFC–AMC released per minute per milligram of protein) ± SEM.
Calpain-induced cleavage of fodrin and huntingtin in vitro. The in vitro proteolysis of endogenous fodrin and huntingtin was studied after incubation (1 hr at 37°C) of control samples (20 µg of protein) with purified µ-calpain (0.2 U; Calbiochem) or recombinant caspase-3 (50 ng; Biomol) in 100 µl of the assay buffer A or B, respectively. Digestion products were analyzed by SDS-PAGE (8–20% gradient gel) followed by Western blot analysis.
Statistical analysis. Results were expressed as means ± SEM. Statistical analysis included Student's t test or one-way ANOVA followed by a post hoc Scheffé F test.
Results
Time course of striatal degeneration and primary mitochondrial impairment in acute and chronic 3-NP models
In the acute model, all 3-NP-treated rats showed symptoms of drowsiness, slowness of movement, and general uncoordination at 6 hr. Histological evaluation indicated that 43% (3/7) of these animals had striatal lesions. Uncoordination and bradykinesia were more pronounced at 12 hr. At this time point, 71% (5/7) of the animals showed tissue abnormalities, including shrinkage of medium neurons and edema in the striatum (data not shown). After 24–48 hr, symptomatic rats had developed severe and permanent dystonia of hindlimbs or recumbency. In these rats, the entire lateral striatum was lesioned with many cells displaying fragmented nuclei or condensed chromatin (Fig. 1B,E). Consistent with this, biochemical analysis showed evidence of nuclear damage in these animals with a significant 20-fold increase in free oligonucleosome levels (an index of DNA fragmentation) compared with control levels (Fig. 2). Thus in the acute model, the onset of striatal lesion was about 6 hr after 3-NP injection and the bulk of degeneration occurred within 24 hr of the 3-NP administration.
View larger version (76K):
[in this window]
[in a new window]
Figure 1. 3-NP-induced preferential degeneration and cell death in the striatum. Sagittal brain sections (Masson-trichrome staining) in control (A, D), acute (B, E), and chronic (C, F) 3-NP models. A–C, Sections of the entire brain at low magnification at two different lateral levels showing the striatal lesion as a pale staining (B, C, arrows). D–F, High magnification of the striatum. Representative normal nuclear staining and the perikarya (devoid of staining, open arrow) of striatal cells (mainly projection neurons) in a control animal is shown in D. Abnormal chromatin condensation and cytoplasm reduction (arrowhead) in neurons is observed in the dorsolateral striatum at 24 hr after acute 3-NP injections (E) and on day 5 in the chronic model (F). Scale bars, 10 µm.
View larger version (24K):
[in this window]
[in a new window]
Figure 2. Evolution of nuclear DNA fragmentation in the striatum in the acute (open bars) and chronic (black bars) 3-NP models. What is shown is relative changes of free oligonucleosomes (i.e., an index of DNA fragmentation due to ongoing cell death) measured in the soluble fraction of striatal homogenates. Each bar corresponds to the mean value ± SEM determined in 6–10 animals. p < 0.0001 compared with control, ANOVA, and post hoc Scheffé F test.
In the chronic model, motor symptoms were prominent on day 4 in all treated rats and worsened on day 5 as previously described (Ouary et al., 2000
The primary effect of 3-NP is the irreversible inhibition of the catalytic site of SDH, the main component of mitochondrial complex II (Brouillet et al., 1999
In the acute model, cortical SDH activity was inhibited by 40% after 3–6 hr (Fig. 3). This SDH inhibition decreased at 12 hr so that SDH activity was at 80% of control and remained at this level up to 48 hr after 3-NP injection. These data show that in an acute experimental paradigm, 3-NP produces a "transient" peak effect on oxidative energy metabolism (Fig. 3).
View larger version (15K):
[in this window]
[in a new window]
Figure 3. 3-NP-induced inhibition of cortical SDH activity in the acute and chronic models. In the chronic model, SDH inhibition reaches
In marked contrast, in the chronic model, SDH activity was progressively inhibited, decreasing by 60–70% on days 3–5 (Fig. 3). These data indicate that very different patterns of SDH inhibition can be achieved depending on the systemic administration of the mitochondrial toxin and that only the chronic model is associated with a sustained 60–70% inhibition of complex II reminiscent of that seen in HD.
Differential patterns of caspase activation are found in acute and chronic models of mitochondrial blockade
After acute administration of 3-NP, in the striatum, caspase-9-related LEHDase activity (Fig. 4A) showed a significant increase at 12 hr compared with controls, and Western blot analysis showed accumulation of the processed p34 subunit of caspase-9 (Fig. 4B). Consistent with this finding, immunohistochemistry of active caspase-9 showed labeled cells in the striatum (Fig. 4C). Caspase-8-related IETDase activity (Fig. 5A) was also significantly increased at 12 hr, and an increase in the processing of caspase-8 was observed by Western blot (Fig. 5B) and immunohistochemistry (Fig. 5C). In the same animals, significant increase in striatal caspase-3-related DEVDase proteolytic activity was detected at 24 hr (Fig. 6A). The presence of processed caspase-3 in the striatum was also demonstrated by Western blot analysis for the active form p17/19 (Fig. 6B). Accumulation of the processed form of caspase-3 in degenerating striatal cells was detected by immunohistochemistry at 12 and 24 hr (Fig. 6C). In summary, the acute model was associated with increased processing of both initiator and effector caspases.
View larger version (59K):
[in this window]
[in a new window]
Figure 4. Study of caspase-9 in rats after acute or chronic 3-NP treatment. A, Caspase-9-related LEHDase proteolytic activity in cerebral cortex and striatum. B, Analysis of striatal and cortical samples by SDS-PAGE followed by Western blot for the active form of caspase-9. Recombinant caspase-9 (Casp.9) was loaded in the left lane as a positive control. Note that accumulation of the p34 subunit of the active form of caspase-9 is detected in the striatum in the acute and chronic 3-NP models. C, Immunohistochemistry of active caspase-9 showing low levels of immunoreactivity in the striatum of control rats, whereas a marked increased labeling (arrows) is detected in the acute model at 12 hr and in the chronic model at day 3. Data are means ± SEM determined in 5–10 animals. N.D., Not detectable.
View larger version (54K):
[in this window]
[in a new window]
Figure 5. Study of caspase-8 in rats after acute or chronic 3-NP treatment. A, Caspase-8-related IETDase proteolytic activity in striatal and cortical homogenates. B, Analysis of brain samples by SDS-PAGE followed by Western blot for the active form of caspase-8. Recombinant caspase-8 (Casp.8) was loaded in the left lane as a positive control. Note that accumulation of the p20 subunit of the active form of caspase-8 is detected only in the striatum in the acute 3-NP model at 12 hr. Ten micrograms of proteins were loaded per lane. C, Immunohistochemical analysis of caspases-8 showing low levels of immunoreactivity in the striatum in control and chronic model, whereas increased striatal labeling is observed in the acute model(arrows). Data are means ± SEM determined in 5–10 animals. N.D., Not detectable.
View larger version (52K):
[in this window]
[in a new window]
Figure 6. Study of caspase-3 in rats after acute or chronic 3-NP treatment. A, Caspase-3-related DEVDase proteolytic activity in striatal and cortical homogenates. B, Analysis by SDS-PAGE followed by Western blot for the active form of caspase-3. Recombinant caspase-3 (Casp.3) was loaded in the left lane as a positive control. Note that accumulation of the p20 subunit of the active form of caspase-3 (seen as a 17/19 kDa doublet) is detected only in the acute 3-NP model at 48 hr. Ten micrograms of protein were loaded per lane. C, Immunohistochemical analysis of activated caspases-3 showing low levels of immunoreactivity in the striatum in control and chronic model, whereas marked increased striatal labeling in detected in the acute model (arrows). N.D., Not detectable. Data are means ± SEM determined in 5–10 animals.
During chronic 3-NP administration, a transient increase in caspase-9-related LEHDase proteolytic activity was detected within the striatum at day 3 (Fig. 4A). Western blot and immunohistochemical analysis of the active form of caspase-9 also showed an accumulation of the processed form of caspase-9 (Fig. 4B,C). Caspase-8-related IETDase activity was not increased in the chronic model (Fig. 5A). Consistent with this, Western blot analysis and immunohistochemistry showed no detectable accumulation of the active caspase-8 subunit p20 (Fig. 5B,D). Similarly, there was no significant increase in caspase-3-related DEVDase activity in the same animals (Fig. 6A) or evidence of increased caspase-3 processing as seen by Western blot analysis using an antibody selective for the p17/19 subunits of active caspase-3 (Fig. 6C). This absence of increase in DEVDase activity was observed in three independent experiments. To detect a possible transient activation of caspase-3 in the chronic model, a group of rats was analyzed every 6 hr from day 2 to day 5. Again, we found no change in DEVDase activity compared with control in this group. Immunohistochemical evaluation of active caspase-3 in these animals showed only a few scattered immuno-reactive neurons in the striatum at day 4 (Fig. 6C).
Interestingly, in the cerebral cortex, which is not sensitive to 3-NP toxicity but in which SDH is similarly inhibited as in the striatum, the same acute and chronic 3-NP rats showed no significant change in DEVDase, LEHDase, and IETDase activity (Fig. 4, 5, 6A). Consistently, Western blot analysis showed no bands corresponding to active caspase-9, -8, and -3 in the cerebral cortex of 3-NP-treated rats (Fig. 4, 5, 6B).
3-NP-induced mitochondrial complex II defect is associated with calpain activation
To further characterize the mechanism of cell death involved in striatal degeneration associated with complex II defect in vivo,we studied the pattern of cleavage of fodrin (non-erythroid
View larger version (36K):
[in this window]
[in a new window]
Figure 7. Calpain activation in acute and chronic 3-NP models. A–C, Homogenates prepared from striatum and cerebral cortex of 3-NP-treated and control (CTRL) rats were analyzed by SDS-PAGE followed by Western blot for fodrin (known substrate of calpain and caspase-3) and assayed for calpain-dependent proteolytic activity using the fluorogenic substrate N-succinyl-LY-AMC (D). E, Western blot analysis ofµ-calpain cleavage in cytosol fractions from striatum and cerebral cortex of 3-NP-treated animals. The typical calpain-dependent cleavage of fodrin appearing as a 145/150 kDa doublet is found in the striatum of both acute (A) and chronic (B) 3-NP models (each lane contains pooled samples from 5–8 animals). Note in A the presence between two nonspecific (N.S.) bands of a 120 kDa band (asterisk), possibly because of a caspase-3-mediated fodrin breakdown product. In B, chronic 3-NP animals were analyzed every 6 hr showing that the intensity of this doublet increases on day 4 and is maximal at day 5. Western blots for fodrin in cerebral cortex were slightly overexposed. C shows that the pattern found in the striatum of 3-NP-treated animals (day 5) is clearly different from the caspase-3-mediated cleavage of fodrin observed after in vitro digestion of control samples with recombinant caspase-3 (CTRL + R. Casp-3). Note the prominent increase in the proteolytic activity of calpain and the presence of cleaved/active form ofµ-calpain in the striatum of chronic 3-NP rats, whereas no changes were found within the cerebral cortex of the same animals. Data are means ± SEM determined in 5–10 animals. N.D., Not detectable.
Chronic 3-NP intoxication resulted in a specific calpain-dependent cleavage of fodrin in the striatum and not in the cerebral cortex (Fig. 7B,C). This was evident as a progressive and selective accumulation of the 145/150 kDa fodrin breakdown products on day 4. Accumulation was maximal at day 5 (Fig. 7A,B). No caspase-3-mediated 120 kDa breakdown product was observed at this time point (Fig. 7C).
To assess the proteolytic activity of calpain in striatum and cerebral cortex more directly, we measured the Ca2+-dependent cleavage of N-succinyl-LY-AMC, a fluorogenic substrate cleaved by calpain, in both models. In the acute model, contrary to Western blot results above, we did not detect any increase in calpain activity at 6, 12, 24, and 48 hr (Fig. 7D). This apparent discrepancy might be explained by a short-lived activation of this enzyme between 6 and 12 hr, leading to the accumulation of calpain-mediated breakdown products of fodrin detected in the striatum at 12 and 24 hr. In the chronic model, calpain activity was prominently increased i.e., 7- to 10-fold, at days 4 and 5 (Fig. 7D) in the striatum, consistent with the accumulation of the fodrin 145/150 kDa doublet.
We analyzed the expression and potential cleavage of µ-calpain by Western blot. In the chronic model, we found an intense 76/78 kDa doublet corresponding to the cleaved/active form of µ-calpain at day 4 (Fig. 7E). Using the same Western blot conditions, this cleaved form of µ-calpain was not found in the striatum in the acute model (Fig. 7E), consistent with a probable short-lived activation of the protease in this model.
Taken together, these results indicate pathological activation of calpains (including µ-calpain) in the acute and chronic 3-NP models. Interestingly, this activation was specific to the striatum: no increased calpain proteolytic activity (Fig. 7D), no cleavage of µ-calpain (Fig. 7E), and no modification of fodrin cleavage (Fig. 7A,B) were detected in the cerebral cortex.
Because the chronic model was capable of reproducing several important features reported in HD patients such as progressive and sustained mitochondrial defects, detectable calpain activation and no major increase in caspase-3 activity, we used this model to further examine the effects produced by calpain inhibition in vivo and its relevance to HD pathogenesis.
CI-1 infusion inhibits calpain in vivo
If calpain activity is central to striatal degeneration produced by sustained mitochondrial defects, inhibiting calpain could have neuroprotective effects. To test this hypothesis, we first examined whether intracerebroventricular infusion of the selective calpain inhibitor CI-1 would inhibit calpain in vivo. We first measured the inhibition of purified µ-calpain induced by striatal soluble fractions taken from rats infused by CI-1 (2.5 µg/hr for 5 d) or vehicle. Control samples produced no significant inhibition of purified µ-calpain. In contrast, fractions from CI-1-treated animals significantly inhibited the activity of the purified enzyme by 70% (Fig. 8A).
View larger version (31K):
[in this window]
[in a new window]
Figure 8. Calpain inhibitor I (CI-1) inhibits calpain in vitro and in vivo. A, Ex vivo estimation of the inhibiting effects of intracerebroventricular infusion of CI-1 (2.5 µg/hr for 5 d) on calpain. Left panel, Striatal cytosol fractions from control (open bar) or 3-NP-treated rats infused with CI-1 (gray bar) were incubated with purifiedµ-calpain before measuring the enzyme activity in vitro. Right panel, Inhibition curve of purifiedµ-calpain by CI-1 in vitro (IC50 = 9.28 nM). B, Top panel, SDS PAGE followed by Western blot for fodrin in striatal membrane fraction prepared from chronic 3-NP-treated and CTRL rats. Note that CI-1 compared with its vehicle (VEH) markedly inhibits in vivo the 3-NP-induced accumulation of the calpain-mediated 145/150 kDa breakdown products of fodrin. Bottom panel, Reduction of the activity of endogenous calpain by infusion of CI-1 in 3-NP-treated rats. C, SDS-PAGE followed by Western blot for huntingtin (Htt) of striatal samples from control (CTRL) or rats treated with 3-NP for 5 d (3-NP). Samples of CTRL rats were loaded after incubation with or without µ-calpain or with or without caspase-3 (R. Casp-3). 3-NP-treated rats received calpain inhibitor 1 (CI-1) or its vehicle only (VEH). The 3-NP treatment induces a reduction of full-length Htt concentrations and the appearance of Htt breakdown products (56 and 65 kDa, arrows) which are similar to those observed after in vitro cleavage of control striatum samples by µ-calpain. Note that in vivo treatment with CI-1 prevents the effects of 3-NP toxicity. N.D., Not detectable.
By measuring the in vitro IC50 value of CI-1 for µ-calpain (9.28 nM) and taking into account the various dilution factors (
Calpain inhibition prevents 3-NP-induced cleavage of huntingtin
Since Htt is cleaved by caspases and calpains into fragments of different molecular weights (Kim et al., 2001Calpain inhibition prevents 3-NP-induced striatal cell death
Because CI-1 could block calpain activation and reduce abnormal processing of the wild-type Htt in the chronic model, we next examined whether CI-1 infusion could prevent 3-NP-induced striatal neurodegeneration. We evaluated the effects of CI-1 at day 5 of the chronic 3-NP treatment, at a time of severe striatal degeneration (Dautry et al., 2000
View larger version (30K):
[in this window]
[in a new window]
Figure 9. Calpain inhibition protects the striatum against chronic 3-NP toxicity. Control rats (CTRL) and rats treated for 5d with 3-NP received continuous infusion of CI-1 or its vehicle (VEH). A, Representative coronal brain sections stained for cytochrome oxidase histochemistry: 3-NP-treated rats that received vehicle showed severe striatal neurodegeneration (open arrow), which is reduced by CI-1 treatment. B, Quantification of the 3-NP-induced striatal lesion volume. C, Quantification of cytochrome oxidase activity. D, ELISA quantification of oligonucleosomes (DNA fragmentation) in the cytosol prepared from the striatum of CTRL and 3-NP-treated rats with or without CI-1 treatment. E, Localization of striatal neurons with DNA fragmentation (TUNEL-positive cells) on coronal sections from 3-NP-treated rats. Section from the CI-1-treated animal with the highest TUNEL-positive cell density is shown. F, Quantification of striatal TUNEL-positive neurons in 3-NP-treated animals. Data are means ± SEM measured in six or seven animals.
Discussion
We used two different animal models of mitochondrial blockade associated either with transient or sustained complex II inhibition, and we found that whereas activation of calpain was observed in both conditions, this was not the case for another death effector protease, caspase-3. In addition, calpain activity was specifically increased in the striatum, a region known to be specifically sensitive to both 3-NP-induced degeneration and HD pathology but not in the cerebral cortex. Finally, calpain inhibition spared striatal cells from neurodegeneration. Together, these data indicate that calpain activation is essential in 3-NP-induced striatal cell death. Because a sustained and partial mitochondrial complex II defect has been reported so far in HD (Brouillet et al., 1999Using a number of biochemical and immunocytochemical evidence, we have shown that caspase-9, -8, and -3 are all activated in the model of transient mitochondrial inhibition. In this situation, the activation of caspase-3 may result from the cleavage of its zymogen form by upstream caspase-9 and/or caspase-8, and this is consistent with our observations that upstream caspase-8 and -9 activation precedes caspase-3 activation in the striatum after acute 3-NP treatment. Although activation of caspase pathways is well known to occur in cell culture models of energy compromise (Du et al., 1997
In clear contrast with the findings in the acute model, we found no activation of caspase-8 during chronic 3-NP treatment. Despite an activation of caspase-9, no caspase-3 activation was detected. The reasons for this are unclear. One hypothesis is that the spreading out of apoptotic events in the chronic model evolving over 5 d would not have allowed us to detect caspase-8 and -3 activation. Although we cannot completely rule out this possibility, the spreading out of apoptotic events would similarly impede detecting caspase-9 activation in the chronically treated rats. A more likely explanation is that specific molecular events may preclude caspase-3 activation and/or the accumulation of active forms of caspase-3 in the chronic model. One possibility is that caspase-9 activation leads to caspase-3 processing but that the rate of degradation of the active forms of caspase-3 is accelerated in this model, preventing the accumulation of functional forms of the death effector protease. In favor of this hypothesis, preliminary data obtained in vitro and in vivo using the chronic 3-NP model show that processed caspase-3 can be degraded by calpain (N. Bizat, J.-M. Hermel, P. Hantraye, S. Krajewski, and E. Brouillet, unpublished observations). Additional studies will be needed to understand the absence of processed forms of caspase-3 in the chronic 3-NP model.
Regardless of the precise mechanisms of caspase-3 regulation, our data demonstrate that one mitochondrial toxin may activate different cell death mechanisms, depending on the pattern of acute and chronic mitochondrial perturbation. Our data also suggest that increased caspase-3 processing may not be strictly required for 3-NP to produce striatal degeneration. This absence of "pathological" caspase-3 processing in the chronic model is reminiscent of the absence of abnormal caspase-3 processing observed in HD patients and in transgenic mice models overexpressing the full-length Htt protein. In line with this, whereas neurotoxicity of quinolinate in wild-type rodents in vivo seems to require caspase-3 processing (Qin et al., 2000
A novel finding of the present work is that the cysteine protease calpain is the essential cell death effector in 3-NP-induced HD-like pathogenesis. In the mammalian brain, calpains (µ-calpain and m-calpain) are present as heterodimers (catalytic 80 kDa subunit and regulatory 30 kDa subunit) in the cytosol and are activated by increases in Ca2+ concentrations (Chan and Mattson, 1999
The mechanisms underlying the "pathological" activation of calpain in 3-NP-treated animals remain speculative but probably involve alterations in Ca2+ homeostasis. Although we show that 3-NP produces a partial blockade of SDH/complex II in our models, further studies will be necessary to characterize in vivo the early consequences of this blockade on mitochondrial membrane potential, radical oxygen species production, Ca2+ uptake capacity, oxidative phosphorylation, and general cellular energy charge. However, it is likely that ATP concentrations are not profoundly modified in the 3-NP models at time points preceding overt tissue damage because (1) we observed caspase-9 activation, which is an ATP-dependent process, and (2) we previously showed increased phosphorylation of the c-jun N-terminal kinase in the chronic model (Garcia et al., 2002
The presence of activated calpain in the striatum of rats with chronic mitochondrial deficits is highly reminiscent of the modifications observed recently in HD patients (Gafni and Ellerby, 2002
The results of the chronic 3-NP model also suggest the existence of a vicious circle in which mitochondrial defects in HD could amplify the toxic effects of mutated Htt. Mitochondrial defects resulting from Htt mutation may lead to anomalies in Ca2+ homeostasis (possibly at the level of pools of Ca2+ associated with NMDA receptors) and "uncontrolled" calpain activation. This would in turn increase cleavage of full length Htt. Given that wild-type Htt is neuroprotective against mutated Htt (Cattaneo et al., 2001
It is possible that the mitochondrial perturbation-induced calpain activation may be also involved in other neurodegenerative disorders such as Alzheimer's disease (Chan and Mattson, 1999
In conclusion, the present study points to calpain as one of the major actors of cell death process in HD and strongly supports the hypothesis that inhibiting calpain activity is a potential therapeutic strategy for the treatment of HD and possibly other neurodegenerative disorders.
Footnotes
Received Nov. 5, 2002; revised Feb. 27, 2003; accepted Mar. 26, 2003.This work was supported by Commissariat à l'Energie Atomique and Centre National de la Recherche Scientifique and National Institutes of Health Grant NS36821 (S.K.). We thank Drs. Kenneth L. Moya and Hirad Hedayat for comments and critical reading of this manuscript.
Correspondence should be addressed to Dr. Emmanuel Brouillet, Unité de Recherche Associée Commissariat à l'Energie Atomique (CEA)-Centre National de la Recherche Scientifique 2210, Service Hospitalier Frédéric Joliot, DRM, DSV, CEA, 4 place du Général Leclerc, 91401 Orsay CEDEX, France. E-mail: brouille{at}shfj.cea.fr.
Copyright © 2003 Society for Neuroscience 0270-6474/03/235020-11$15.00/0
References
Albin RL, Greenamyre JT (1992) Alternative excitotoxic hypotheses. Neurology 42: 733–738.
[Abstract/Free Full Text] Beal MF (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illness? Ann Neurol 31: 119–130.[Web of Science][Medline]
Beal MF (2000) Energetics in the pathogenesis of neurodegenerative disorders. Trends Neurosci 7: 298–304.
Beal MF, Brouillet E, Jenkins B, Ferrante R, Kowall N, Miller J, Storey E, Srivastava R, Rosen B, Hyman BT (1993) Neurochemical and histologic characterization of the striatal lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13: 4181–4192.[Abstract]
Benchoua A, Guegan C, Couriaud C, Hosseini H, Sampaio N, Morin D, Onteniente B (2001) Specific caspase pathways are activated in the two stages of cerebral infarction. J Neurosci 21: 7127–7134.
[Abstract/Free Full Text] Blum D, Gall D, Galas MC, d'Alcantara P, Bantubungi K, Schiffmann SN (2002) The adenosine A1 receptor agonist ADAC exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid of neurotoxicity. J Neurosci 22: 9122–9133.
[Abstract/Free Full Text] Brouillet E, Guyot M-C, Mittoux V, Altairac S, Condé F, Palfi S, Hantraye P (1998) Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in Rat. J Neurochem 70: 794–805.[Web of Science][Medline]
Brouillet E, Condé F, Beal MF, Hantraye P (1999) Replicating Huntington's disease in experimental animals. Prog Neurobiol 59: 427–458.[Web of Science][Medline]
Browne SE, Bowling AC, Mac Garvey U, Baik MJ, Berger SC, Muqit MK, Bird ED, Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41: 646–653.[Web of Science][Medline]
Calabresi P, Gubellini P, Picconi B, Centonze D, Pisani A, Bonsi P, Greengard P, Hipskind RA, Borrelli E, Bernardi G (2001) Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J Neurosci 21: 5110–5120.
[Abstract/Free Full Text] Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S (2001) Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci 24: 182–188.[Web of Science][Medline]
Cepeda C, Ariano MA, Calvert CR, Flores-Hernandez J, Chandler SH, Leavitt BR, Hayden MR, Levine MS (2001) NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 66: 525–539.[Web of Science][Medline]
Chan SL, Mattson MP (1999) Caspase and calpain substrates: roles in synaptic plasticity and cell death. J Neurosci Res 58: 167–190.[Web of Science][Medline]
Dautry C, Vauffrey F, Brouillet E, Bizat N, Condé F, Bloch G, Hantraye P (2000) Early N-acetylaspartate depletion is a marker of neuronal dys-function in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J Cereb Blood Flow Metab 20: 789–799.[Web of Science][Medline]
DiFiglia M (1990) Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci 13: 286–289.[Web of Science][Medline]
Di Rosa G, Odrijin T, Nixon RA, Arancio O (2002) Calpain inhibitors: a treatment for Alzheimer's disease. J Mol Neurosci 19: 135–141.[Web of Science][Medline]
Du Y, Dodel RC, Bales KR, Jemmerson R, Hamilton-Byrd E, Paul SM (1997) Involvement of a caspase-3-like cysteine protease in 1-methyl-4-phenylpyridinium-mediated apoptosis of cultured cerebellar granule neurons. J Neurochem 69: 1382–1388.[Web of Science][Medline]
Duan W, Zhiong G, Mattson M (2000) Participation of Par-4in the degeneration of striatal neurons induced by metabolic compromise with 3-nitropropionic acid. Exp Neurol 165: 1–11.[Medline]
Gafni J, Ellerby LM (2002) Calpain activation in Huntington's disease. J Neurosci 22: 4842–4849.
[Abstract/Free Full Text] Garcia M, Vanhoutte P, Pages C, Besson MJ, Brouillet E, Caboche J (2002) Activation of the c-Jun-N-terminal kinase/c-Jun module occurs in striatal neurons in response to 3-nitropropionic acid: a comparative in vivo and in vitro analysis. J Neurosci 22: 2174–2184.
[Abstract/Free Full Text] Greene JG, Greenamyre JT (1995) Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate. J Neurochem 64: 430–436.[Web of Science][Medline]
Greene JG, Sheu S-S, Gross RA, Greenamyre JT (1998) 3-nitropropionic acid exacerbates N-methyl-D-aspartate toxicity in striatal culture by multiple mechanisms. Neuroscience 84: 503–510.[Web of Science][Medline]
Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Shapira AH (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39: 385–389.[Web of Science][Medline]
Hackam AS, Singaraja R, Wellington CL, Metzler M, McCutcheon K, Zhang T, Kalchman M, Hayden MR (1998) The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol 141: 1097–1105.
[Abstract/Free Full Text] Harper PS (1991) Huntington's disease (Harper PS, ed). London: Saunders.
Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, Hirsch EC (2000) Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 97: 2875–2880.
[Abstract/Free Full Text] Hermel J-M, Dirkx R, Solimena M (1999) Post-translational modifications of ICA512 a receptor tyrosine phosphatase-like protein of secretory granules. Eur J Neurosci 11: 2609–2620.[Web of Science][Medline]
Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971–983.[Web of Science][Medline]
Jenkins BG, Koroshetz WJ, Beal MF, Rosen R (1993) Evidence for an energy metabolic defect in Huntington's Disease using localized proton spectroscopy. Neurology 43: 2689–2693.
[Abstract/Free Full Text] Jenkins BG, Rosas HD, Chen YCI, Makabe T, Myers R, MacDonald M, Rosen BR, Beal MF, Koroshetz WJ (1998) 1H NMR spectroscopy studies of Huntington's Disease correlation with CAG repeat numbers. Neurology 50: 1357–1365.
[Abstract/Free Full Text] Kim GW, Copin JC, Kawase M, Chen SF, Sato S, Gobbel GT, Chan PH (2000) Excitotoxicity is required for induction of oxidative stress and apoptosis in mouse striatum by the mitochondrial toxin 3-nitropropionic acid. J Cereb Blood Flow Metab 20: 119–129.[Web of Science][Medline]
Kim YJ, Yi Y, Sapp E, Wang Y, Cuiffo B, Kegel KB, Qin ZH, Aronin N, DiFiglia M (2001) Caspase-3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains associate with membranes and undergo calpain-dependent proteolysis. Proc Natl Acad Sci USA 98: 12784–12789.
[Abstract/Free Full Text] Krajewski S, Krajewska M, Ellerby LM, Welsh K, Xie Z, Deveraux QL, Salvesen GS, Bredesen DE, Rosenthal RE, Fiskum G, Reed JC (1999) Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia. Proc Natl Acad Sci USA 96: 5752–5757.
[Abstract/Free Full Text] Laforet GA, Sapp E, Chase K, McIntyre C, Boyce FM, Campbell M, Cadigan BA, Warzecki L, Tagle DA, Reddy PH, Cepeda C, Calvert CR, Jokel ES, Klapstein GJ, Ariano MA, Levine MS, DiFiglia M, Aronin N (2001) Changes in cortical and striatal neurons predict behavioral and electro-physiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci 21: 9112–9123.
[Abstract/Free Full Text] Lee M-S, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405: 360–364.[Medline]
Leist M, Volbracht C, Fava E, Nicotera P (1998) 1-Methyl-4-phenylpy ridinium induces autocrine excitotoxicity protease activation and neuronal apoptosis. Mol Pharmacol 54: 789–801.
[Abstract/Free Full Text] McDonald MC, Mota-Filipe H, Paul A, Cuzzocrea S, Adbelrahman M, Harwood S, Plevin R, Chatterje PK, Yaqoob MM, Thiemermann C (2001) Calpain inhibitor I reduces the activation of nuclear factor-kappaB and organ injury/dysfunction in hemorrhagic shock. FASEB 15: 171–186.
[Abstract/Free Full Text] Mittoux V, Ouary S, Monville C, Lisovoski F, Poyot T, Conde F, Escartin C, Robichon R, Brouillet E, Peschanski M, Hantraye P (2002) Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration. J Neurosci 22: 4478–4486.
[Abstract/Free Full Text] Namura S, Zhu J, Fink K, Endres M, Srinivasan A, Tomaselli KJ, Yuan J, Moskowitz MA (1998) Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia. J Neurosci 18: 3659–3668.
[Abstract/Free Full Text] Newcomb-Fernandez JK, Zhao X, Pike BR, Wang KK, Kampfl A, Beer R, DeFord SM, Hayes RL (2001) Concurrent assessment of calpain and caspase-3 activation after oxygen-glucose deprivation in primary septohippocampal cultures. J Cereb Blood Flow Metab 21: 1281–1294.[Medline]
Nicholson DW, Thornberry NA (1997) Caspases: killer proteases. Trends Biochem Sci 22: 299–306.[Web of Science][Medline]
Ohgoh M, Shimizu H, Ogura H, Nishizawa Y (2000) Astroglial trophic support and neuronal cell death: Influence of cellular energy level on type of cell death influenced by mitochondrial toxin in cultured rat cortical neurons. J Neurochem 75: 925–933.[Web of Science][Medline]
Ouary S, Bizat N, Altérac S, Ménétrat H, Mittoux V, Condé F, Hantraye P, Brouillet E (2000) Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionate in rats: implications for neuroprotection studies. Neurosci 97: 521–530.[Web of Science][Medline]
Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5: 731–736.[Web of Science][Medline]
Peng TI, Greenamyre JT (1998) Privileged access to mitochondria of calcium influx through N-methyl-D-aspartate receptors. Mol Pharmacol 53: 974–980.
[Abstract/Free Full Text] Petersen A, Mani K, Brundin P (1999) Recent advances on the pathogenesis of Huntington's disease. Exp Neurol 157: 1–18.[Web of Science][Medline]
Qin Z, Wang Y, Chasea TN (2000) A caspase-3-like protease is involved in NF-kappaB activation induced by stimulation of N-methyl-D-aspartate receptors in rat striatum. Brain Res Mol Brain Res 80: 111–122.[Medline]
Sanchez I, Xu CJ, Juo P, Kakizaka A, Blenis J, Yuan J (1999) Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22: 623–633.[Web of Science][Medline]
Saudou F, Finkbeiner S, Devys D, Greenberg M (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95: 55–66.[Web of Science][Medline]
Sawa A, Wiegand GW, Cooper J, Margolis R, Sharp AH, Lawler JF, Greenamyre JT, Snyder SH, Ross C (1999) Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 5: 1194–1198.[Web of Science][Medline]
Schulz JB, Weller M, Matthews RT, Heneka MT, Groscurth P, Martinou JC, Lommatzsch J, Coelin RV, Wulner U, Loschmann PA, Beal MF, Dichgans J, Klockgether T (1998) Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. Cell Death Differ 5: 847–857.[Web of Science][Medline]
Simpson JR, Isacson O (1993) Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum. Exp Neurol 121: 57–64.[Web of Science][Medline]
Stoka V, Turk B, Schendel S, Cirman T, Snipas SJ, Ellerby L, Bredesen D, Freeze H, Abrahamson M, Broemme D, Krajewski S, Reed JC, Yin X-M, Turk V, Salvesen G (2001) Lysosomal protease pathways to apoptosis: cleavage of BID, not pro-caspases, is the most likely route. J Biol Chem 276: 3149–3157.
[Abstract/Free Full Text] Tabrizi SJ, Cleeter MW, Xuereb J, Taanman J-W, Cooper JM, Shapira AHV (1999) Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 45: 25–32.[Web of Science][Medline]
Tompa P, Baki A, Schad E, Friedrich P (1996) The calpain cascade. Mucalpain activates m-calpain. J Biol Chem 271: 33161–33164.
[Abstract/Free Full Text] Wang K (2000) Calpain and caspase: can you tell the difference? Trends Neurosci 23: 20–26.[Web of Science][Medline]
Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, Gafni J, Bredesen D, Hersch SM, Leavitt BR, Roy S, Nicholson DW, Hayden MR (2002) Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci 22: 7862–7872.
[Abstract/Free Full Text] Wüllner U, Young A, Penney J, Beal MF (1994) 3-nitropropionic acid toxicity in the striatum. J Neurochem 63: 1772–1781.[Web of Science][Medline]
Zeevalk GD, Derr-Yellin E, Nicklas WJ (1995) Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade. J Pharmacol Exp Ther 275: 1124–1130.
[Abstract/Free Full Text] Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA (2002) Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33: 849–860.[Web of Science][Medline]
This article has been cited by other articles:
T. Ratovitski, M. Gucek, H. Jiang, E. Chighladze, E. Waldron, J. D'Ambola, Z. Hou, Y. Liang, M. A. Poirier, R. R. Hirschhorn, et al.
Mutant Huntingtin N-terminal Fragments of Specific Size Mediate Aggregation and Toxicity in Neuronal Cells
J. Biol. Chem., April 17, 2009; 284(16): 10855 - 10867.
[Abstract] [Full Text] [PDF]
M. D. Covington, D. D. Arrington, and R. G. Schnellmann
Calpain 10 is required for cell viability and is decreased in the aging kidney
Am J Physiol Renal Physiol, March 1, 2009; 296(3): F478 - F486.
[Abstract] [Full Text] [PDF]
C. M. Cowan, M. M. Y. Fan, J. Fan, J. Shehadeh, L. Y. J. Zhang, R. K. Graham, M. R. Hayden, and L. A. Raymond
Polyglutamine-Modulated Striatal Calpain Activity in YAC Transgenic Huntington Disease Mouse Model: Impact on NMDA Receptor Function and Toxicity
J. Neurosci., November 26, 2008; 28(48): 12725 - 12735.
[Abstract] [Full Text] [PDF]
H. Akashiba, Y. Ikegaya, N. Nishiyama, and N. Matsuki
Differential Involvement of Cell Cycle Reactivation between Striatal and Cortical Neurons in Cell Death Induced by 3-Nitropropionic Acid
J. Biol. Chem., March 7, 2008; 283(10): 6594 - 6606.
[Abstract] [Full Text] [PDF]
G. Kroemer, L. Galluzzi, and C. Brenner
Mitochondrial Membrane Permeabilization in Cell Death
Physiol Rev, January 1, 2007; 87(1): 99 - 163.
[Abstract] [Full Text] [PDF]
C. Jacquard, Y. Trioulier, F. Cosker, C. Escartin, N. Bizat, P. Hantraye, J. M. Cancela, G. Bonvento, and E. Brouillet
Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation
FASEB J, May 1, 2006; 20(7): 1021 - 1023.
[Abstract] [Full Text] [PDF]
A. Benchoua, Y. Trioulier, D. Zala, M.-C. Gaillard, N. Lefort, N. Dufour, F. Saudou, J.-M. Elalouf, E. Hirsch, P. Hantraye, et al.
Involvement of Mitochondrial Complex II Defects in Neuronal Death Produced by N-Terminus Fragment of Mutated Huntingtin
Mol. Biol. Cell, April 1, 2006; 17(4): 1652 - 1663.
[Abstract] [Full Text] [PDF]
M. Zhou and M. Baudry
Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors.
J. Neurosci., March 15, 2006; 26(11): 2956 - 2963.
[Abstract] [Full Text] [PDF]
R. Pardo, E. Colin, E. Regulier, P. Aebischer, N. Deglon, S. Humbert, and F. Saudou
Inhibition of Calcineurin by FK506 Protects against Polyglutamine-Huntingtin Toxicity through an Increase of Huntingtin Phosphorylation at S421
J. Neurosci., February 1, 2006; 26(5): 1635 - 1645.
[Abstract] [Full Text] [PDF]
T. Shang, J. Joseph, C. J. Hillard, and B. Kalyanaraman
Death-associated Protein Kinase as a Sensor of Mitochondrial Membrane Potential: ROLE OF LYSOSOME IN MITOCHONDRIAL TOXIN-INDUCED CELL DEATH
J. Biol. Chem., October 14, 2005; 280(41): 34644 - 34653.
[Abstract] [Full Text] [PDF]
M. Canonaco, M. Madeo, R. Alo, G. Giusi, T. Granata, A. Carelli, A. Canonaco, and R. M. Facciolo
The Histaminergic Signaling System Exerts a Neuroprotective Role against Neurodegenerative-Induced Processes in the Hamster
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 188 - 195.
[Abstract] [Full Text] [PDF]
L. E. Broker, F. A.E. Kruyt, and G. Giaccone
Cell Death Independent of Caspases: A Review
Clin. Cancer Res., May 1, 2005; 11(9): 3155 - 3162.
[Abstract] [Full Text] [PDF]
N. Stefanova, M. Reindl, M. Neumann, C. Haass, W. Poewe, P. J. Kahle, and G. K. Wenning
Oxidative Stress in Transgenic Mice with Oligodendroglial {alpha}-Synuclein Overexpression Replicates the Characteristic Neuropathology of Multiple System Atrophy
Am. J. Pathol., March 1, 2005; 166(3): 869 - 876.
[Abstract] [Full Text] [PDF]
L. Stefanis
Caspase-Dependent and -Independent Neuronal Death: Two Distinct Pathways to Neuronal Injury
Neuroscientist, February 1, 2005; 11(1): 50 - 62.
[Abstract] [PDF]
M. J. Calkins, R. J. Jakel, D. A. Johnson, K. Chan, Y. W. Kan, and J. A. Johnson
Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription
PNAS, January 4, 2005; 102(1): 244 - 249.
[Abstract] [Full Text] [PDF]
N. Bizat, J.-M. Hermel, S. Humbert, C. Jacquard, C. Creminon, C. Escartin, F. Saudou, S. Krajewski, P. Hantraye, and E. Brouillet
In Vivo Calpain/Caspase Cross-talk during 3-Nitropropionic Acid-induced Striatal Degeneration: IMPLICATION OF A CALPAIN-MEDIATED CLEAVAGE OF ACTIVE CASPASE-3
J. Biol. Chem., October 31, 2003; 278(44): 43245 - 43253.
[Abstract] [Full Text] [PDF]
This Article Abstract 
Full Text (PDF) A correction has been published Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager 
Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (77) Citing Articles via Google Scholar Google Scholar Articles by Bizat, N. Articles by Brouillet, E. Search for Related Content PubMed PubMed Citation Articles by Bizat, N. Articles by Brouillet, E.
|
|
|
|
 |
|